Mevrometostat plus enzalutamide in metastatic castration-resistant
Mevrometostat plus enzalutamide in metastatic castration-resistant prostate cancer
$26.04PFE last close Jun 16Pfizer ($PFE)
$26.04PFE last close Jun 16Closed
Will PF-06821497 (mevrometostat) with enzalutamide meet the primary endpoint of radiographic progression-free survival (rPFSOutcome measureProgression-Free Survival (PFS)rPFS is defined as the time from randomization to first objective evidence of radiographic progression by RECIST v1.1 or PCWG3 guidelines by blinded independent central review, or death, whichever occurs first.Primary outcome | Randomization up to approximately 3 yearsClinicalTrials.gov outcome) in NCT06629779?
Paper Trading
Create account to trade
Metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer has spread and keeps growing despite very low testosterone. Delaying radiographic progression can mean the cancer stays controlled longer on scans.